Unresectable Hepatocellular Carcinoma
72
20
33
16
Key Insights
Highlights
Success Rate
84% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 39/100
4.2%
3 terminated out of 72 trials
84.2%
-2.3% vs benchmark
15%
11 trials in Phase 3/4
50%
8 of 16 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 16 completed trials
Clinical Trials (72)
Radiation Therapy With Protons or Photons in Treating Patients With Liver Cancer
Delivering a Diuretic Into the Liver Artery Followed by Plugging up the Artery to Starve Out Liver Cancer Cells
Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant
Durvalumab and Tremelimumab After Radioembolization for the Treatment of Unresectable, Locally Advanced Liver Cancer
Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer
Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.
An Observational Study to Learn More About How Well a Treatment Works When Given After Treatment With Atezolizumab and Bevacizumab or Another Similar Combination of Drugs in Adults With Liver Cancer That Cannot be Treated With Surgery
TACE Plus Camrelizumab and Apatinib for Unresectable Hepatocellular Carcinoma
A Multicenter Clinical Study of Combined Therapy for Unresectable Hepatocellular Carcinoma
Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors
Imfinzi/Imjudo uHCC Japan PMS _ Japan Post-Marketing Surveillance (PMS) Study
Atezolizumab+Bevacizumab+SBRT in Unresectable HCC
A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab
68Ga PSMA PET Imaging for the Treatment of Advanced Liver Cancer
Selective Internal Radiation Therapy (SIRT) Using SIR-Spheres® Y-90 Resin Microspheres on DoR & ORR in Unresectable Hepatocellular Carcinoma Patients
Safety and Efficacy of TareSphere in Patients With Unresectable Hepatocellular Carcinoma
Yttrium-90 Radiation Segmentectomy for Hepatocellular Carcinoma
A Phase II Trial of Organoid Drug Sensitivity Testing to Guide Therapy in Unresectable Hepatocellular Carcinoma
Downstaging Unresectable Hepatocellular Carcinoma to Resectable Disease With Combined Immunotherapy and Stereotactic Beamed Radiotherapy: a Pilot Study